Amycretin

Amycretin, also known by its development code NN9487 and INN name Zenagamtide, is a novel unimolecular peptide designed to act as a dual agonist at the glucagon-like peptide-1 receptor (GLP-1R) and the amylin receptor (AMYR). This compound is a 68-amino-acid peptide in which distinct GLP-1R-agonist and AMYR-agonist moieties are covalently linked within a single molecule by a short linker composed of four glycine residues and one glutamic acid residue. This structural design represents a genuine innovation in peptide therapeutics by combining both receptor activities in one molecule, rather than relying on the co-administration of two separate peptides, as seen in some other investigational approaches.

The molecular formula of amycretin is C343H550N94O116, with an average molecular weight of approximately 7,847 Daltons. At Verified Peptides, we recognize the significance of this molecular complexity and size, particularly given the pharmaceutical challenge of achieving effective delivery for peptides of this magnitude.

Amycretin's development includes a unique dual formulation strategy that distinguishes it from most other peptides in research pipelines. It is being developed simultaneously as a once-weekly subcutaneous injectable and as a once-daily oral formulation. The oral bioavailability of a peptide this large is a notable pharmaceutical achievement and a point of considerable scientific and commercial interest. This parallel formulation development aims to provide flexibility in dosing and administration routes for future research applications.

Regarding its regulatory status, amycretin remains an investigational compound and has not been approved by the U.S. Food and Drug Administration (FDA) for any indication. No New Drug Application (NDA) has been filed, and no FDA Breakthrough Therapy or Fast Track designation has been confirmed for this molecule. Phase 3 clinical development is in its early stages, with the AMAZE-1 obesity trial having commenced on February 24, 2026. This trial plans to enroll approximately 1,150 participants and has a primary completion date estimated around June 2029. Additionally, a separate Phase 3 program targeting type 2 diabetes is planned to start in 2026.

At Verified Peptides, we supply research-grade amycretin for laboratory research use, distinct from the pharmaceutical-grade product under clinical development by Novo Nordisk. Our provision of this investigational peptide supports preclinical and translational research efforts exploring its pharmacological profile and therapeutic potential.

For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.

Amycretin (development code NN9487, INN Zenagamtide) is a novel unimolecular peptide agonist targeting both the GLP-1 receptor (GLP-1R) and amylin receptor (AMYR). At Verified Peptides, we recognize its unique molecular design, consisting of a 68-amino-acid sequence in which distinct GLP-1R and AMYR agonist moieties are covalently linked by a short peptide linker composed of four glycine residues and one glutamic acid residue. This single-molecule approach differentiates amycretin from combination therapies that co-administer separate peptides, representing a genuine structural innovation in dual receptor agonism. The molecular formula is C343H550N94O116 with an average molecular weight of approximately 7,847 Da.

From a pharmaceutical development perspective, amycretin is notable for being developed in parallel as both a once-weekly subcutaneous injection and a once-daily oral formulation, an uncommon achievement for a peptide of this size. Oral bioavailability in such a large peptide is a significant scientific and commercial distinction, setting amycretin apart from many other injectable-only GLP-1 or amylin receptor agonists.

The clinical development of amycretin remains in early stages. At Verified Peptides, we emphasize that no FDA approval, Breakthrough Therapy, or Fast Track designation has been granted. Phase 3 development has only recently commenced, with the AMAZE-1 obesity trial initiating in February 2026 and an estimated enrollment of approximately 1,150 participants. A separate Phase 3 program targeting type 2 diabetes is planned to begin in 2026. No New Drug Application (NDA) has been filed to date.

Published clinical data include a first-in-human Phase 1 study (The Lancet, June 20, 2025, PMID 40550229) conducted at a single research center in San Antonio, Texas. This randomized, double-blind, placebo-controlled, multipart trial enrolled 144 participants with overweight or obesity across four parts between May 2022 and January 2024. Subcutaneous amycretin was administered once weekly at doses up to 60 mg. Across all parts, 364 treatment-emergent adverse events (TEAEs) were reported in 89 of 144 participants (62%), all characterized as mild or moderate in severity. Gastrointestinal events were the most frequently observed, accounting for 49% of TEAEs and occurring in 81% of participants experiencing any adverse event. The study demonstrated dose-proportional plasma pharmacokinetics and confirmed a safety and tolerability profile suitable for further clinical development. No deaths occurred during the trial.

A subsequent Phase 1b/2a randomized controlled study (The Lancet, PMID 40550231) further evaluated subcutaneous amycretin in individuals with overweight or obesity. The results from this study supported progression into Phase 3 development, reinforcing the compound’s safety and pharmacodynamic profile. At Verified Peptides, we note that these peer-reviewed publications are accessible via PubMed and NIH resources for detailed examination.

Additionally, topline data from a Phase 2 trial in adults with type 2 diabetes were announced in November 2025 and presented at the American Diabetes Association meeting in 2026. This trial evaluated both subcutaneous and oral amycretin formulations. At the 40 mg subcutaneous dose, participants achieved approximately 14.5% mean weight loss alongside a 1.8-percentage-point reduction in HbA1c. The oral dosing arm demonstrated up to 10.1% weight loss compared to 2.5% in the placebo group. These results, while not yet peer-reviewed, provide early evidence of the dual agonist’s potential metabolic effects and highlight the significance of oral delivery.

At Verified Peptides, we offer research-grade amycretin intended exclusively for laboratory investigation of the dual GLP-1R/AMYR mechanism, distinct from the pharmaceutical formulations under clinical development by Novo Nordisk. This distinction ensures that researchers can explore the compound’s biochemical properties and receptor interactions without implying clinical or therapeutic use.

For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.

Amycretin represents a distinctive advancement in peptide therapeutics through its unimolecular design, integrating both GLP-1 receptor (GLP-1R) and amylin receptor (AMYR) agonist activities within a single 68-amino-acid peptide. At Verified Peptides, we emphasize that this single-molecule approach, linked by a short chain of four glycine residues and one glutamic acid residue, is a genuine structural innovation. Unlike combination therapies such as cagrilintide plus semaglutide, which require co-administration of separate peptides, amycretin’s architecture consolidates dual receptor targeting into one molecule. This design potentially simplifies pharmacokinetics and dosing strategies in research settings by reducing the complexity inherent in multi-peptide regimens.

Another notable facet of amycretin is its pharmaceutical development trajectory aiming for both once-weekly subcutaneous and once-daily oral formulations. At Verified Peptides, we recognize that achieving oral bioavailability for a peptide of approximately 7,847 Da molecular weight is a significant scientific milestone. Large peptides typically face degradation and poor absorption in the gastrointestinal tract, necessitating injectable administration. Amycretin’s parallel development of an oral form distinguishes it from most other GLP-1 and amylin receptor agonists, which remain injectable-only. This dual formulation strategy may offer valuable flexibility for laboratory investigations into peptide delivery mechanisms and pharmacodynamics.

Regarding its developmental status, amycretin is currently the earliest-stage candidate among GLP-1/amylin receptor dual agonists advancing toward late-stage clinical evaluation. At Verified Peptides, we note that Phase 3 development has only recently commenced, with the AMAZE-1 obesity trial initiating in February 2026 and expected to enroll approximately 1,150 participants. A separate Phase 3 program targeting type 2 diabetes is planned for 2026 but has not yet started. This early Phase 3 positioning contrasts with other compounds in this class that are further along in clinical development or regulatory review. Researchers utilizing amycretin for investigational purposes should be aware that it remains an investigational peptide without FDA approval or regulatory designations such as Breakthrough Therapy or Fast Track status.

For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.

At Verified Peptides, we recognize the critical importance of purity and reliable sourcing in research-grade amycretin to support rigorous laboratory investigations. Amycretin, a 68-amino-acid unimolecular peptide agonist of both GLP-1 and amylin receptors, presents unique challenges due to its complex structure and substantial molecular weight of approximately 7847 Da. To ensure that the research material meets stringent quality standards, we implement comprehensive quality assurance protocols that include high-performance liquid chromatography (HPLC) to confirm purity levels typically exceeding 95%, alongside mass spectrometry analyses to verify molecular identity and structural integrity. These orthogonal analytical techniques provide confidence in the peptide’s authenticity and batch-to-batch consistency, which are essential for reproducible experimental outcomes.

At Verified Peptides, we emphasize that our research-grade amycretin is distinct from the pharmaceutical-grade compound under development by Novo Nordisk. While Novo Nordisk’s product is advancing through early Phase 3 clinical trials with both injectable and oral formulations, our material is intended solely for laboratory research use and is not suitable for human administration or clinical applications. We supply amycretin as a non-GMP peptide, explicitly for investigative purposes, enabling researchers to explore its pharmacological properties, receptor interactions, and potential mechanisms without conflating research-grade supply with regulated pharmaceutical products.

At Verified Peptides, we also provide third-party certificates of analysis (COA) with each batch of amycretin, detailing purity, identity, and analytical data to support traceability and regulatory compliance in research settings. This transparency facilitates informed experimental design and reliable data interpretation. Our commitment to quality and integrity in sourcing ensures that investigators receive amycretin that meets the demanding requirements of peptide research, supporting the advancement of scientific knowledge in this emerging therapeutic area.

For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.

At Verified Peptides, we recommend that research-grade amycretin, as a lyophilized peptide, be stored under conditions that preserve its structural integrity and biological activity for laboratory use. Lyophilized amycretin should be kept at -20°C or colder to minimize degradation and maintain potency over time. Avoid exposure to moisture and repeated temperature fluctuations, which can compromise peptide stability.

For reconstitution, use sterile, nuclease-free water or buffer appropriate for your experimental design, taking care to avoid vigorous agitation that might cause peptide denaturation. Once reconstituted, amycretin solutions are generally less stable than the lyophilized form and should be stored at 2–8°C if used within a short timeframe, typically no longer than several days. For longer storage, aliquoting and freezing at -80°C is advisable to reduce freeze-thaw cycles, which can lead to peptide aggregation or loss of activity.

Repeated freeze-thaw cycles should be avoided to maintain the peptide’s functional properties. Shelf-life depends on storage conditions and formulation but is typically several months to a year when stored properly in lyophilized form. At Verified Peptides, we emphasize strict adherence to these storage and handling guidelines to ensure consistent research results when working with amycretin as a dual GLP-1 and amylin receptor agonist peptide.

For research purposes only. Not for human consumption. Not FDA approved. Consult a licensed physician.